The most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...

Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a pioneer in democratizing wellness, today reported results for the year ended December 31, 2024. Recent ...

In the video below, Androsavich explains how Ginkgo Datapoints generates data and provides it as a service to pharma ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

Reshma Shetty co-founded Ginkgo Bioworks in 2008, a leading organism design company. As President and COO, she has overseen ...

Certara’s AI strategy and FDA-aligned offerings fuel growth across drug discovery and trials, with expanding margins. Read ...

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

Ginkgo Bioworks (DNA) announced a new contract with the Advanced Research Projects Agency for Health, or ARPA-H, alongside partners Tritica ...